Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Time-Restricted eating may fight frailty in prostate cancer patients

NCT ID NCT05968144

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study looks at whether eating only during a 10-hour window each day can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty means losing strength and energy, which can make it hard to live independently. The study will compare a group that follows time-restricted eating with a group that eats normally, measuring changes in frailty and body responses over 12 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Maryland, Baltimore

    Baltimore, Maryland, 21201, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

time-restricted eating (10-hour eating window)

What this could lead to

If it works, this could point toward a simple dietary strategy to help older adults on hormone therapy stay stronger and more independent.

What could go wrong

This is a very small, early-phase study (30 people) testing feasibility, not effectiveness. The results may not apply to everyone, and dietary changes can be hard to stick with.

Conditions

The condition(s) this trial relates to.

breast neoplasm Frailty prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.